Literature DB >> 21839137

Olanzapine stimulates proliferation but inhibits differentiation in rat oligodendrocyte precursor cell cultures.

Sohei Kimoto1, Aya Okuda, Michihiro Toritsuka, Takahira Yamauchi, Manabu Makinodan, Hiroaki Okuda, Kouko Tatsumi, Yu Nakamura, Akio Wanaka, Toshifumi Kishimoto.   

Abstract

In the developing brain, oligodendrocyte progenitor cells (OPCs) proliferate, migrate, and differentiate into mature oligodendrocytes (OLs) capable of myelinating axons. Recently, OPCs have been identified as an abundant and widespread population in the adult as well as in the developing animal. Current research indicates that these OPCs in the adult brain can proliferate and differentiate into myelinating OLs, albeit with different potentialities from those in developing animals. Multiple lines of evidence, from neuroimaging, postmortem, and genetic association studies, have implicated OL and myelin dysfunction in the pathogenesis of schizophrenia. If altered OL function is involved in pathogenesis, OPCs may thus respond to antipsychotic drugs during the recovery process. In the present study, we used primary OPC cultures from optic nerve of newborn Wistar rat pups to investigate the direct effects of haloperidol (HPD; a typical antipsychotic) and olanzapine (OLZ; an atypical antipsychotic) on the proliferation and differentiation of OPCs. Our results showed that 1) OLZ treatment significantly increased the number of viable OPCs when compared to HPD treatment at relatively high concentrations, 2) OLZ treatment suppressed the expression of myelin basic protein (MBP), and to a greater extent than HPD treatment, and 3) these pharmacological effects may be mediated via the ERK signaling pathway. Our findings suggest a glial mechanism for the antipsychotic action of OLZ, and a role for oligodendrocyte-lineage cells in the pathogenesis and treatment of schizophrenia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839137     DOI: 10.1016/j.pnpbp.2011.07.011

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

Review 1.  Monoamines in glioblastoma: complex biology with therapeutic potential.

Authors:  Seamus Patrick Caragher; Robert Raymond Hall; Riasat Ahsan; Atique U Ahmed
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 2.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

3.  Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma.

Authors:  Seamus P Caragher; Jack M Shireman; Mei Huang; Jason Miska; Fatemeh Atashi; Shivani Baisiwala; Cheol Hong Park; Miranda R Saathoff; Louisa Warnke; Ting Xiao; Maciej S Lesniak; C David James; Herbert Meltzer; Andrew K Tryba; Atique U Ahmed
Journal:  J Neurosci       Date:  2019-01-16       Impact factor: 6.167

Review 4.  Electrophysiological properties of NG2(+) cells: Matching physiological studies with gene expression profiles.

Authors:  Valerie A Larson; Ye Zhang; Dwight E Bergles
Journal:  Brain Res       Date:  2015-09-15       Impact factor: 3.252

5.  White matter changes associated with antipsychotic treatment in first-episode psychosis.

Authors:  Philip R Szeszko; Delbert G Robinson; Toshikazu Ikuta; Bart D Peters; Juan A Gallego; John Kane; Anil K Malhotra
Journal:  Neuropsychopharmacology       Date:  2013-10-16       Impact factor: 7.853

6.  Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone.

Authors:  Haiyun Xu; Hong-Ju Yang; Xin-Min Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-06-01       Impact factor: 5.270

7.  Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases.

Authors:  B Di Benedetto; R Rupprecht
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

8.  Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.

Authors:  Erik Johnsen; Igne Sinkeviciute; Else-Marie Løberg; Rune A Kroken; Kenneth Hugdahl; Hugo A Jørgensen
Journal:  BMC Psychiatry       Date:  2013-09-30       Impact factor: 3.630

Review 9.  Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia.

Authors:  Danielle Gouvêa-Junqueira; Ana Caroline Brambilla Falvella; André Saraiva Leão Marcelo Antunes; Gabriela Seabra; Caroline Brandão-Teles; Daniel Martins-de-Souza; Fernanda Crunfli
Journal:  Front Psychiatry       Date:  2020-04-30       Impact factor: 4.157

Review 10.  A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.

Authors:  Rune A Kroken; Else-Marie Løberg; Tore Drønen; Renate Grüner; Kenneth Hugdahl; Kristiina Kompus; Silje Skrede; Erik Johnsen
Journal:  Front Psychiatry       Date:  2014-02-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.